This phase 3 trial in acute bacterial skin and skin structure infections showed IV followed by oral delafloxacin to be noninferior to IV vancomycin/aztreonam combination therapy and well tolerated. Oral delafloxacin appears to maintain the initial response with IV delafloxacin.

Patients with AS had higher levels of OPN compared with controls. The plasma OPN level was correlated with serum ALP, OCN and CTX-I levels, but not with disease activity in AS. OPN might be involved in bone remodelling rather than in inflammation in AS.

No abstract

No abstract

Spinal implant infection is a rare but significant complication of spinal fusion surgery, and the most common pathogen is Staphylococcus aureus. It is difficult to treat due to this pathogen's biofilm-forming ability and antibiotic resistance. We evaluated the therapeutic outcome of treatments for S aureus spinal implant infections. We retrospectively reviewed all patients with S aureus spinal implant infections at 11 tertiary-care hospitals over a 9-year period. Parameters predictive of treatment failure and recurrence were analyzed by Cox regression. Of the 102 patients with infections, 76 (75%) were caused by methicillin-resistant S aureus (MRSA) and 51 (50%) were late-onset infections. In all, 83 (81%) patients were managed by debridement, antibiotics, and implant retention (DAIR) and 19 (19%) had their implants removed. The median duration of all antibiotic therapies was 52 days. During a median follow-up period of 32 months, treatment failure occurred in 37 (36%) cases. The median time to treatment failure was 113 days, being <1 year in 30 (81%) patients. DAIR (adjusted hazard ratio [aHR], 6.27; P = .01) and MRSA infection (aHR, 4.07; P = .009) were independently associated with treatment failure. Rifampin-based combination treatments exhibited independent protective effects on recurrence (aHR, 0.23; P = .02). In conclusion, among patients with S aureus spinal implant infections, MRSA and DAIR were independent risk factors for treatment failure, and these risk factors were present in the majority of patients. In this difficult-to-treat population, the overall treatment failure rate was 36%; rifampin may improve the outcomes of patients with S aureus spinal implant infections.

No abstract

·············································································································································································Data was collected for the period 2002 and 2013, from The National Health Insurance Service Health-Examinee Cohort Database, to evaluate the association between periodontal disease (PD) and vasculogenic erectile dysfunction (VED). Univariate and multivariate logistic regression models applied to a longitudinal retrospective database assessed the association between PD and VED, while adjusting for confounders of socio-demographic factors (age, household income, insurance status, health status, residence area, and smoking status) and systemic disease (cerebral infarction, myocardial infarction, angina pectoris, hypertension, diabetes mellitus, osteoporosis, lipid metabolism disturbances, and obesity). The univariate analysis revealed that VED was positively and significantly related to PD (OR = 2.07; 95% CI 1.73-2.49; P < 0.001). This was confirmed in the multivariate analysis, after adjusting for socio-demographic and systemic disease (OR = 1.45; 95% CI 1.21-1.75; P < 0.001). Using information from a longitudinal retrospective cohort database and considering the limitations of this study, we found positive and significant associations between PD and VED. Further studies are required to assess the mechanism underlying the association between PD and VED. KEY WORDS: Cohort, Erectile dysfunction, Periodontal disease 서 론 치주질환은 치조골, 백악질, 치주인대, 치은을 아우르는 치아 주위 조직의 포괄적인 염증성 파괴로 정의되며, 전 세계 인구의 절반 이상이 이환되어 있는 것으로 보고되는 매우 유병률 높은 만성 질환이다[1]. 국내에서는 2015년 현재 치은염 및 치주질환으로 치과에 내원한 외래 환자 수 가 1,300만 명을 넘어섰으며, 외래 질환 중 요양급여지출 총액은 급성 기관지염보다 많은 1조원을 넘어서고 있다. 특히, 2013년 예방 스케일링의 보험 확대 이후, 우리나라 에서의 치주질환의 진단 및 치료에 대한 관심이 지속적으 로 높아지고 있으며, 이에 따라 치과에 내원하여 치주질환 진단을 받고 치료를 받는 환자 수가 연간 평균 16.7%씩 증가하고 있다[2]. 미국국립보건원은 발기부전을 성생활을 영위하는데 있 어서 충분히 발기가 되지 않거나 유지되지 않은 상태로 정 의하였으며, 이러한 상태가 3개월 이상 지속되었을 경우에 일반적인 질환의 의미의 발기부전으로 정의하였다[3]. 전 세계적으로 1억 명 이상의 성인 남성이 경도에서 중증도 에 이르는 발기부전을 가지고 있는 것으로 예상되며, 한국 인에 있어서는 40% 이상의 성인에서 발기부전을 보이는 것으로 보고되었다[4]. 발기부전은 일반적으로 40세 이상 에서 높은 유병률을 보이며, 특히, 40대에서 70대 사이의 남성 중 10% 가까이는 중증의 발기부전을 가지고 있는 것

No abstract